查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1198148

PTA 球囊導管市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

Pta Balloon Catheter Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 111 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內（2022-2027 年），PTA 球囊導管市場預計將以 7.5% 左右的複合年增長率增長。

COVID-19 大流行的爆發導致就診人數減少，從而減少了選擇外科手術的患者數量，從而影響了市場的增長。 根據國家醫學圖書館 2021 年發表的一項研究，與大流行前 (BC) 時期相比，大流行後 (AC) 時期與 ST 段抬高型心肌梗死 (STEMI) 相關，該活動導致血管造影術。它的特點是導致直接經皮冠狀動脈介入治療 (PPCI) 的激活次數顯著減少。 STEMI 發病率的降低促使血管造影和 PPCI 的減少。 與大流行開始前相比，大流行開始後從門到氣球 (D2B) 的時間平均增加了 20%。 因此，在大流行的早期階段，COVID-19 對市場的影響是不利的。

心血管疾病和外周動脈疾病患病率上升、老年人口增加以及微創手術的使用增加是推動市場增長的一些主要因素。 在全球範圍內，心髒病的發病率正在增加，這對人們的身心健康產生了負面影響。 因此，有效和先進的診斷和治療程序的需求一直是 PTA 球囊導管。 因此，預計在預測期內市場將增加。 據歐洲心臟網2021年公佈的數據顯示，歐盟有超過6000萬人患有心血管疾病，每年將診斷出近1300萬心血管疾病新病例。 因此，由於心血管疾病的高發，介入心臟手術在世界範圍內呈上升趨勢。 因此，未來 PTA 球囊導管市場有望增長。

然而，導管通常會導致靜脈血栓形成，從而導致肺栓塞，這在某些情況下可能是致命的。 血栓形成導致導管阻塞和導管尖端周圍的薄護套腔內、靜脈和附壁血栓。 由於反複使用導管，接受心導管術的患者發生導管相關血流感染的風險增加。 因此，與導管相關的風險和並發症可能會在未來幾年阻礙 PTA 球囊導管的市場增長。 然而，這些可以通過技術進步來克服。

PTA球囊導管市場趨勢

PTA球囊導管市場，冠心病領域有望佔據較大市場份額

在過去的 30 年裡，心血管疾病一直是全球死亡的主要原因。 久坐不動的生活方式是許多慢性疾病（如糖尿病和心血管疾病）的主要原因之一。 缺乏運動、飲酒和不健康食品以及吸煙等有害習慣已導致肥胖症流行，而肥胖症是各種心血管疾病的罪魁禍首。 治療這些疾病的外科手術增加了對經皮腔內血管成形術 (PTA) 球囊導管的需求。 2021 年發表在 Pub Med Central 上的一項研究發現，冠狀動脈疾病是全球死亡率和傷殘調整生命年 (DALYs) 損失的首要原因。 這一負擔大部分落在了低收入和中等收入國家身上，這些國家每年約有 12900 萬 DALYs，而人群中冠狀動脈疾病發病率的增加導致對導管的需求增加，導致預計在預測期內推動 PTA 球囊導管市場的增長。 例如，最近一項可能導致鈣化血管治療方式轉變的創新是衝擊波血管內碎石系統，該系統於 2021 年 2 月被美國食品和藥物管理局 (FDA) 批准用於冠狀動脈。 這涉及將低壓氣球連接到導管並發射聲波能量以分解鈣。

此外，波士頓科學公司正在進行美國首個藥物塗層球囊（DCB）臨床試驗，以評估DCB在冠狀動脈支架內再狹窄（ISR）患者中的安全性和有效性。宣布IDE考試“代理”已經啟動。

這樣，由於上述新興市場的發展，預計該市場在預測期內將顯著增長。

北美有望在預測期內主導市場

美國是全球受影響最嚴重的國家，因為泌尿系統和心血管疾病的患病率增加，預計對 PTA 球囊導管的需求將增加，從而預計將推動 PTA 球囊導管市場的增長。

這方面的背景是眾多 PTA 球囊導管製造商、供應商和分銷商的存在、心血管疾病的高患病率、先進醫療基礎設施的存在以及患者對新興微創手術意識的提高。有一些因素. 此外，對微創手術的日益偏好，如微創冠狀動脈旁路移植術和微創心胸外科 (MICS)，也促進了北美市場的增長。 心髒病的流行預計將推動市場增長。 根據美國疾病控制與預防中心 (CDC) 的數據，2020 年 9 月，心髒病是美國最主要的心血管疾病。 每年約有 805,000 名美國人心髒病發作。 隨著心髒病數量的增加，對滿足未滿足需求所需的適當治療程序和設備的需求也在增加。 因此，預計在預測期內會出現增長。

此外，該地區創新產品的推出也促進了市場的增長。 例如，2021 年 6 月，Neurescue 的 NEURESCUE 設備獲得了美國食品和藥物管理局的 510k 許可，這是“世界上第一個智能球囊導管”，專為主動脈等大血管的臨時閉塞而設計。

此外，不斷上升的醫療保健成本和提高的疾病意識（尤其是在美國和加拿大）正在推動該地區整體市場的增長。

PTA 球囊導管市場競爭對手分析

PTA 球囊導管市場分散且競爭激烈，由幾家大型企業組成。 從市場份額的角度來看，目前幾家大型企業佔據了市場主導地位。 目前主導市場的公司包括 Medtronic plc、Terumo Corporation、Cardinal Health、Boston Scientific Corporation、Natec Medical、AndraTec、Cook Medical、Biotronik、Abbot、Koninklijke Philips、B. Braun Melsungen AG、Becton、Cardionovum GmbH 等。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動力
    • 泌尿系統疾病和心血管疾病的患病率增加
    • 對微創手術的需求
    • 老齡化社會、缺乏運動和不健康的飲食習慣
  • 市場製約因素
    • 血管成形術費用高
    • 與導管相關的風險和並發症
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第五章市場細分（價值基礎，單位：百萬美元）

  • 按材料類型
    • 聚氨酯
    • 尼龍
  • 通過申請
    • 冠狀動脈疾病
    • 外周血管疾病
  • 最終用戶
    • 醫院或診所
    • 門診手術中心
    • 其他
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Medtronic plc
    • Terumo Corporation
    • Cardinal Health
    • Boston Scientific Corporation
    • Natec Medical
    • AndraTec
    • Cook Medical
    • Biotronik
    • Abbot
    • Koninklijke Philips
    • B. Braun Melsungen AG
    • Becton
    • Cardionovum GmbH

第7章 市場機會今後動向

簡介目錄
Product Code: 90876

The PTA Balloon Catheter market is expected to register a CAGR of about 7.5% during the forecast period (2022-2027).

The onset of the COVID-19 pandemic has led to a reduction in the number of patient visits that reduced the number of patients opting for surgical procedures, thereby impacting the market growth. As per the study published by the National Library of Medicine in 2021, Compared to periods before initiation of pandemic (BC), the after initiation of pandemic (AC) period was characterized by a marked reduction in the number of activations for ST-elevation myocardial infarction (STEMI), number of activations leading to angiography and number of activations leading to primary percutaneous coronary intervention (PPCI). A decline in STEMI activations drove the reductions in angiography and PPCI volumes. Relative to periods before initiation of the pandemic, the door to balloon (D2B) times after initiation of the pandemic period increased on average by 20%. As a result, the impact of COVID-19 on the market was adverse during the initial phase of the pandemic.

The rising prevalence of cardiovascular disorders and peripheral artery disease, the growing geriatric population, and an increasing number of minimally invasive surgeries are some of the key factors boosting the market growth. Globally there has been an increase in the incidence of cardiac disease, which is negatively impacting people's physical and mental well-being. Thus, the demand for effective and advanced diagnostics and treatment procedures were PTA balloon catheters. Therefore, the market is expected to increase in the forecast period. According to the data published by the European Heart network in 2021 reported that in the European Union more than 60 million people live with Cardiovascular disease and close to 13 million new cases of cardiovascular diseases are diagnosed every year. Hence, due to the high frequency of cardiovascular diseases, interventional heart procedures are increasing around the world. As a result, the PTA balloon catheter market is expected to increase in the coming year.

However, catheters are often associated with vein thrombosis, which may lead to pulmonary embolism and, in some cases, may prove to be fatal. Thrombosis can result in obstruction of a catheter, which includes a fibrin sheath around the intraluminal, venous, and mural thrombosis at the catheter tip. Patients who undergo cardiac catheterization are at a higher risk of catheter-associated bloodstream infections due to repeated use of catheters. Therefore, risks and complications associated with catheters may impede the growth of the market for PTA Balloon Catheters in the coming years. However, they can be overcome with technological advancements.

PTA Balloon Catheter Market Trends

The Coronary Artery Disease Segment is Expected to Hold a Major Market Share in the PTA Balloon Catheter Market

Cardiovascular diseases have become the leading cause of death worldwide in the past three decades. A sedentary lifestyle is one of the major causes leading to many chronic disorders such as diabetes and cardiovascular ailments. Harmful habits such as lack of physical activity, consumption of alcohol and unhealthy food, and smoking have resulted in a growing prevalence of obesity, which in turn leads to various cardiovascular diseases. Surgical intervention for the treatment of such disorders has increased the demand for percutaneous transluminal angioplasty (PTA) balloon catheters. According to a study published by Pub Med Central in 2021, Coronary artery disease is the foremost single cause of mortality and loss of Disability Adjusted Life Years (DALYs) globally. A large number of this burden falls on low and middle-income countries accounting for nearly129 a million DALYs annually, with the growing incidence of coronary artery disease among the people expected to increase demand for catheters, which in turn is expected to drive the growth of the PTA balloon catheter market over the forecast period. For instance, a recent innovation that may offer a paradigm shift in how calcified vessels are treated is the Shockwave Intravascular Lithotripsy system approved by the Food and Drug Administration(FDA) in February 2021 for coronary artery use in February 2021. It combines a low-pressure balloon mounted on a catheter that delivers bursts of sonic energy to crack the calcium.

In addition to this, Boston Scientific Corporation announced it had initiated the AGENT IDE trial for the Agent Drug-Coated Balloon (DCB), the first clinical trial in the United States to evaluate the safety and effectiveness of a DCB in patients with coronary in-stent restenosis (ISR).

Thus, due to the above-mentioned developments, the market is expected to witness significant growth over the forecast period.

North America is Expected to Dominate the Market Over the Forecast Period

The United States is the most affected country across the world, as the increasing prevalence of urological and cardiovascular diseases is expected to increase demand for PTA balloon catheters, which in turn is expected to fuel the PTA balloon catheter market growth over the forecast period.

This can be attributed to factors such as the presence of a large number of PTA balloon catheter manufacturers, suppliers, and distributors, the high prevalence of cardiovascular disorders, the presence of sophisticated healthcare infrastructure, and an increase in patient awareness about emerging minimally invasive surgeries in the region. In addition, the growing preference for minimally invasive surgeries, such as minimally invasive coronary bypass and Minimally Invasive Cardiothoracic Surgery (MICS), is contributing to market growth in North America. The prevalence of cardiac diseases is expected to boost the growth of the market. Also, according to the Centres for Disease Control and Prevention (CDC), in September 2020, heart disease was the leading cardiovascular disease in the United States. Every year about 805,000 Americans has a heart attack. As the number of heart diseases is increasing, there is a growing demand for the proper treatment procedures and devices required to fulfill the unmet needs. Hence are expected to show growth over the forecast period.

Also, the innovative product launches in this region are contributing to the growth of the market. For instance, In June 2021, Neurescue received the 510k clearance from the United States Food and Drug Administration for their NEURESCUE device, 'the world's first intelligent balloon catheter,' devised for the temporary occlusion of large vessels such as the aorta.

Moreover, high expenditure on healthcare, especially in the United States and Canada, along with increased awareness about the disease, is fueling the growth of the overall regional market to a large extent. ​

PTA Balloon Catheter Market Competitor Analysis

The PTA Balloon Catheter market is fragmented and competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Medtronic plc, Terumo Corporation, Cardinal Health, Boston Scientific Corporation, Natec Medical, AndraTec, Cook Medical, Biotronik, Abbot, Koninklijke Philips, B. Braun Melsungen AG, Becton, Cardionovum GmbH, and others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Urological and Cardiovascular Diseases
    • 4.2.2 Demand for Minimally-Invasive Surgeries
    • 4.2.3 Growing Aging Population and Lack of Physical Activities and Unhealthy Diet
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Angioplasty
    • 4.3.2 Risk and Complication Associated with Catheterization Procedures
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - in USD Million)

  • 5.1 By Material Type
    • 5.1.1 Polyurethane
    • 5.1.2 Nylon
  • 5.2 By Application
    • 5.2.1 Coronary Artery Disease
    • 5.2.2 Peripheral Vascular Disease
  • 5.3 By End User
    • 5.3.1 Hospitals or Clinics
    • 5.3.2 Ambulatory Surgery Centers
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Medtronic plc
    • 6.1.2 Terumo Corporation
    • 6.1.3 Cardinal Health
    • 6.1.4 Boston Scientific Corporation
    • 6.1.5 Natec Medical
    • 6.1.6 AndraTec
    • 6.1.7 Cook Medical
    • 6.1.8 Biotronik
    • 6.1.9 Abbot
    • 6.1.10 Koninklijke Philips
    • 6.1.11 B. Braun Melsungen AG
    • 6.1.12 Becton
    • 6.1.13 Cardionovum GmbH

7 MARKET OPPORTUNITIES AND FUTURE TRENDS